- Home
- VNRX vs CLSD Comparison
VNRX vs CLSD Comparison
Compare VNRX & CLSD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VNRX
- CLSD
- Stock Information
- Founded
- VNRX N/A
- CLSD 2011
- Country
- VNRX United States
- CLSD United States
- Employees
- VNRX N/A
- CLSD N/A
- Industry
- VNRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- CLSD Biotechnology: Pharmaceutical Preparations
- Sector
- VNRX Health Care
- CLSD Health Care
- Exchange
- VNRX Nasdaq
- CLSD Nasdaq
- Market Cap
- VNRX 52.4M
- CLSD 59.1M
- IPO Year
- VNRX N/A
- CLSD 2016
- Fundamental
- Price
- VNRX $0.67
- CLSD $0.83
- Analyst Decision
- VNRX Strong Buy
- CLSD Strong Buy
- Analyst Count
- VNRX 5
- CLSD 4
- Target Price
- VNRX $3.88
- CLSD $4.75
- AVG Volume (30 Days)
- VNRX 307.2K
- CLSD 180.1K
- Earning Date
- VNRX 08-13-2025
- CLSD 08-11-2025
- Dividend Yield
- VNRX N/A
- CLSD N/A
- EPS Growth
- VNRX N/A
- CLSD N/A
- EPS
- VNRX N/A
- CLSD N/A
- Revenue
- VNRX $1,308,361.00
- CLSD $3,764,000.00
- Revenue This Year
- VNRX $563.72
- CLSD $143.33
- Revenue Next Year
- VNRX $160.43
- CLSD N/A
- P/E Ratio
- VNRX N/A
- CLSD N/A
- Revenue Growth
- VNRX 64.16
- CLSD N/A
- 52 Week Low
- VNRX $0.40
- CLSD $0.70
- 52 Week High
- VNRX $0.94
- CLSD $1.65
- Technical
- Relative Strength Index (RSI)
- VNRX 48.82
- CLSD 50.70
- Support Level
- VNRX $0.62
- CLSD $0.80
- Resistance Level
- VNRX $0.76
- CLSD $0.90
- Average True Range (ATR)
- VNRX 0.08
- CLSD 0.04
- MACD
- VNRX -0.02
- CLSD 0.01
- Stochastic Oscillator
- VNRX 16.73
- CLSD 45.38
About VNRX VolitionRX Limited
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.
About CLSD Clearside Biomedical Inc.
Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing a proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.